RMRaffaella Marcheselli

Raffaella Marcheselli

*This is an algorithmically generated author record based on publicly available information.

Raffaella Marcheselli has a total of 127 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A phase 2 study of autologous stem cell transplantation as salvage therapy for older patients with aggressive B-cell lymphoma prospectively evaluated by comprehensive geriatric assessment: the FIL_RECANZ study

    by Alessandra Tucci, Alessandro Re, Chiara Pagani, Luigi Marcheselli, Raffaella Marcheselli, Francesco Malaspina, Federica Cavallo, Vittorio Ruggero Zilioli, Manuela Zanni, Donato Mannina, et al.

    The FIL_RECANZ (ClinicalTrials.gov: NCT02371161) is a prospective study evaluating salvage with autologous stem cell transplantation (ASCT) in aggressive B-cell lymphoma patients aged 65 - 75, fit according to the FIL Geriatric Assessment (CGA). Seventy patients were analyzed who received salvage with three cycles of a platinum-based regimen. Response to salvage was 44% (21 complete, 10 partial remissions). Twenty-seven responding subjects underwent ASCT following BEAM/FEAM conditioning with a median of 5.6 × 106 CD34+ cells/kg reinfused: 24 (89%) obtained complete remission, in 22 lasting > 12 months. After a median of 28 months from ASCT, 2-year event-free survival was 54%, with the most common grade 3-4 non-hematological toxicity consisting of gastrointestinal (10%) and infectious (8%). No treatment-related mortality was recorded within 100 days following ASCT. Our data indicate that CGA enables fit older patients to undergo ASCT with favorable tolerance and efficacy. These results may serve as a benchmark to assess more effective pre-ASCT therapies.

  • Open Access

    Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma

    by Raffaella Marcheselli, Alessia Bari, Tamar Tadmor, Luigi Marcheselli, Maria Christina Cox, Robel Papotti, Angela Ferrari, Luca Baldini, Paolo Gobbi, Ilana Levy, et al.

    The main purpose of this study was to assess whether it is possible to improve the prognostic impact of international prognostic index (IPI) score by combining it with peripheral blood counts. Thus, we evaluated the prognostic power of lymphocyte, neutrophil, and monocyte counts in 520 patients with diffuse large B cell lymphoma treated with R‐CHOP, confirming that these parameters have a strong impact on overall survival (OS). Using revised IPI (R‐IPI), 44% of patients were categorized as poor‐risk and showed an OS at 5 years of 46%. As OS at 5 years of the 520 patients is 67%, it is clearly evident that R‐IPI tends to overestimate the proportion of patients with poor prognosis. Accordingly, in an attempt to improve the discriminating power of R‐IPI, we evaluated and compared three different scores by combining the neutrophil lymphocyte ratio (NLR) and absolute monocyte count (AMC) with the following values: (a) IPI score 3‐5, (b) age > 60 years and performance status, (c) age ≥ 65 years and LDH > ULN. The three indexes studied, had a similar 5 years OS for the high‐risk group (46%‐52%), but the proportion of patients classified as poor‐risk were 37%, 20%, and 32%, respectively, which are lower than 44% identified with R‐IPI. Thus, while R‐IPI overestimates the number of high‐risk patients, after applying our models, it is possible to recognize patients who are truly at high‐risk. Of the three scores, the most accurate appears to be that based on NLR, AMC, LDH > ULN and age ≥ 65 years, which identifies 32% of high‐risk patients, correlating well with what is seen in clinical practice.


  • A concise review of lenalidomide therapy for follicular lymphoma

    by Alessia Bari, Raffaella Marcheselli, Monica Barbolini, Paola Ferri, Stefano Sacchi, Samantha Pozzi

    Introduction: Lenalidomide, first introduced for the treatment of multiple myeloma in 2008, has been used in the treatment of various subtypes of non-Hodgkin lymphoma (NHL). Considering its mechanism of action, it has been associated with rituximab, showing strong activity in follicular lymphomas (FL). As the chemo-free treatments are a topic of great relevance we decided to prepare a concise review mainly directed to clinicians involved in the management of NHL patients. Areas covered: This article reviews the clinical trials published since 2008 utilizing lenalidomide alone or in combination for treating relapsed/refractory or treatment naïve patients with FL. Expert opinion: With current rituximab plus chemotherapy treatments, almost all patients will relapse from the disease over time. The introduction of lenalidomide in the management of FL showed good efficacy in particular in combination with rituximab (R2). The high rates of durable responses obtained with the R2 combination were similar to those previously observed with standard chemotherapy plus rituximab. If the results of the ongoing multicenter pivotal phase 3 trial (NCT01476787) are favorable for R2 combination, we may move towards a chemotherapy-free approach in the management of FL, which would finally turn a dream into reality

  • Open Access

    Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide

    by Andrew J. Yee, Parameswaran Hari, Raffaella Marcheselli, Anuj K. Mahindra, Diana D. Cirstea, Tyler A. Scullen, Jill N. Burke, Scott J. Rodig, Teru Hideshima, Jacob P. Laubach, et al.

    Summary: Everolimus, an oral mammalian target of rapamycin (mTOR) inhibitor, has been studied in multiple myeloma (MM) but lacks significant single agent activity. Based on preclinical studies showing synergistic activity of mTOR inhibitors with lenalidomide, we studied the combination of lenalidomide and everolimus in relapsed or refractory MM in a phase I clinical trial. We assessed patient samples using gene expression, Western blotting and immunohistochemistry to probe the mTOR pathway. Twenty‐six patients were evaluable for toxicity. Dose‐limiting toxicities included grade 4 neutropenia and thrombocytopenia. The maximum tolerated dose was lenalidomide 15 mg and everolimus 5 mg for 21 d with a 7 d rest period. Grade 3/4 adverse events included thrombocytopenia (35%) and neutropenia (42%). The overall response rate was 65% (1 complete response + 4 partial response + 10 minimal response). The median progression‐free survival was 5·5 months and median overall survival was 29·5 months. Biomarker data demonstrated downregulation of phosphorylated p70S6K. Gene expression profiling suggested activation of mTOR in responders versus non‐responders. The combination of lenalidomide and everolimus was well tolerated with predictable toxicities and showed responses in a heavily pretreated population. When confirmed with larger patient numbers, this analysis may guide patient selection for future clinical trials of mTOR inhibition in MM.


  • Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population‐based analysis

    by Samantha Pozzi, Luigi Marcheselli, Alessia Bari, Eliana V. Liardo, Raffaella Marcheselli, Stefano Luminari, Micol Quaresima, Claudia Cirilli, Paola Ferri, Massimo Federico, et al.

    Summary: Novel treatments for multiple myeloma (MM) have shown promising results in clinical trials, but the advantage in unselected patients is still unclear. In order to evaluate whether novel therapies impact survival of MM patients, we performed a population‐based analysis on data collected by the Modena Cancer Registry from 1989 to 2009. The analysis evaluated 1206 newly diagnosed MM patients collected in the years 1988–96 (conventional therapy), 1997–05 (high dose melphalan and autologous transplant), and 2006–09 (novel agents era). Both relative survival (RS) and overall survival (OS) improved over the years, but not equally in the three groups. For patients aged <65 years, RS improved in 1997–05 and 2006–09 compared with previous years and a trend to improvement was observed from 1997–05 to 2006–09. For patients aged 65–74 years, RS improved significantly in 2006–09 compared with 1988–96 and 1997–05. No amelioration was observed for patients 75+ years old. OS confirmed RS. In conclusion, the survival of MM patients aged <65 and, in particular, 65–74 years, has improved over time, especially after 2006. This observation provides circumstantial evidence that novel therapies might impact patient survival. Despite the limits of this study, these data refer to an unselected population, giving a picture of every day clinical practice.


  • Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma

    by Luigi Marcheselli, Raffaella Marcheselli, Alessia Bari, ElianaValentina Liardo, Fortunato Morabito, Luca Baldini, Maura Brugiatelli, Francesco Merli, Nicola Di Renzo, Stefano Sacchi

    The effects of radiotherapy (RT) after chemotherapy in patients with diffuse large B-cell lymphoma (DLBCL) remain unclear; several trials have yielded conflicting results. This study examined the effect of RT after cyclophosphamide, doxorubicin, vincristine, and prednisone + rituximab (R-CHOP) treatment on event-free (EFS) and overall (OS) survival. Data from 216 patients with DLBCL who were enrolled in two clinical trials at Italian Lymphoma Study Group sites and were subjected to six R-CHOP cycles and involved-field radiotherapy (IFRT) were retrospectively analyzed. IFRT treatment yielded significant EFS benefit, with a 66% reduction in the risk of death and/or disease progression. Cox analysis, when adjusted for age, gender, stage, performance status (PS), lactate dehydrogenase (LDH), and disease bulk, confirmed the significant EFS benefit of IFRT. The role of RT in DLBCL in the rituximab era is unclear. Future studies must take into account new radiation techniques and the response to chemotherapy based on functional imaging. Prospective randomized trials incorporating response-adapted therapy and modern radiation techniques are needed.


  • A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant

    by Stefano Sacchi, Raffaella Marcheselli, Antonio Lazzaro, Fortunato Morabito, Alberto Fragasso, Nicola Di Renzo, Enrico Balleari, Santo Neri, Giovanni Quarta, Raimondo Ferrara, et al.

    Several trials comparing the efficacy of standard melphalan and prednisone (MP) therapy with MP plus thalidomide (MPT) in elderly patients with multiple myeloma (MM) have been reported, with inconsistent results. The primary goal of our study was to evaluate the efficacy and toxicity of MP versus MPT in newly diagnosed patients with MM who were transplant-ineligible or over age 65. A total of 135 patients were enrolled. Either minimal response or better or partial response or better were more frequent with MPT treatment (p = 0.001). After a median follow-up of 30 months, median progression-free survival (PFS) and overall survival (OS) were 33 and 52 months for MPT versus 22 and 32 months for MP, respectively. The comparison showed a significant advantage for MPT versus MP in PFS (p = 0.02) and only a trend for OS (p = 0.07). Severe adverse events were observed more frequently with MPT. In conclusion, our results show an improved activity of MPT at a cost of increased toxicity. We believe that MPT can be considered one of the new standard of care for elderly or transplant-ineligible patients with MM.


  • Open Access

    Risk for second malignancies in non-Hodgkin’s lymphoma survivors: a meta-analysis

    by M. Pirani, R. Marcheselli, L. Marcheselli, A. Bari, M. Federico, S. Sacchi

    Background: Late side-effects are becoming an important issue in non-Hodgkin’s lymphoma (NHL) survivors. We intended to estimate pooled relative risk (RR) of secondary malignant neoplasms (SMNs), to evaluate site-associated RR and the impact of different treatments. Design: We carried out an electronic search of Medline and EMBASE seeking articles investigating the risk of SMNs and reporting RR measures. The studies were evaluated for heterogeneity before meta-analysis and for publication bias. Pooled RRs were estimated using fixed- and random-effects models. Results: A total of 23 studies met the inclusion criteria. Pooled RRs of SMNs overall and for solid tumors were 1.88 and 1.32, respectively. We found an excess of risk for several specific cancer sites. Radiotherapy alone did not increase the risk for SMNs, while chemotherapy and combined treatments augmented the RR. Regression analyses revealed a positive significant association for all SMNs with total body irradiation, and for solid SMNs with younger age. No publication bias was observed. Conclusions: Our results indicate that NHL patients experience a higher risk for SMNs than the general population and that various treatments have different impact on RR. More information will be necessary to evaluate possible interactions with genetic susceptibility and environmental exposure.


  • Open Access

    THERAPY-RELATED MYELOID NEOPLASM IN NON-HODGKIN LYMPHOMA SURVIVORS

    by Alessia Bari, Luigi Marcheselli, Raffaella Marcheselli, Eliana Valentina Liardo, Samantha Pozzi, Paola Ferri, Stefano Sacchi

    Background: Relatively little information on secondary cancers is available for Non-Hodgkin lymphoma (NHL) treated patients as treatments have been less effective compared to those for Hodgkin Lymphoma. Recently, evolving chemotherapy (CHT) in combination with monoclonal antibodies, sometime supplemented with radiotherapy (RT) have improved survival outcome of NHL patients and the use of autologous and allogeneic bone marrow transplantation for relapsed patients have further improved long term survival for some histological subtypes. As a results of these advances secondary malignancies are becoming an important issue in NHL survivors. Design and Methods: In the last few years, our group performed 4 researches about second neoplasms in NHL survivors: (1) Secondary malignancies after treatment for indolent NHL; (2) Secondary malignancies after treatment for Diffuse Large B Cell Lymphoma (DLBCL); (3) Meta analysis on the risk of second malignancies in NHL survivors; (4) Incidence of second myeloid malignancies (SMyM) in patients treated for NHL, evaluated on Modena Cancer Registry (MCR) database. Results: In the first study we analyzed 563 patients with indolent NHL enrolled in Gruppo Italiano Studio Linfomi (GISL) trials from 1988 to 2003; results showed that, after a median follow-up of 62 months, 39 patients (6.9%) developed secondary cancer (12 Myelodisplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML), and 27 solid tumours). The cumulative incidence (CI) of secondary cancer at 12 years was 10.5%. In the second paper we considered 1280 patients with DLBCL enrolled in GISL trials from 1988 to 2003; with a median follow-up of 51 months 48 patients (3.8%) developed a second cancer (8 MDS/AML, 5 other hematologic malignancies and 35 solid tumours). The CI of second cancer was 8.2% at 15 years. The third research consist in a meta-analysis in which we carried out an electronic search seeking articles investigating the risk of second malignant neoplasm (SMN) after NHL treatment; we have found 1,521 papers and after selection we considered 19 studies available for our aims. Our results indicated that NHL patients experienced a higher risk for SMN (1.88-fold increased risk) than the general population, in particular the standardized incidence risk (SIR) for secondary AML was 11.07. In province of Modena in the period 2000-2008 we found that the SIR to develop a second tumor after NHL was 1.63 and it grew up for second haematological malignancies (SIR 1.99). As concern the incidence of MDS and/or AML in Modena province on MCR we found a total of 9 NHL with SMyM (3 AML and 6 MDS) with a higher risk than expected (SIR 8.8, 95% CI: 4.0-16.6), in particular the SIR for secondary AML was 5.7. Conclusions: Overall our results observed either in patients enrolled in clinical trials or on database from hospital and population registry showed an increased risk to develop a second tumour in CHT/RT-treated patients. By meta-analysis, more impressive results have been observed considering only SMyM . Data from MCR confirm the trend for NHL treated to be at higher risk to develop SMN and in particular SMyM . In conclusion patients treated for NHL are at increased risk to develop secondary neoplasm. Thus for NHL survivors a long term monitoring should be considered with a follow-up longer than five years as usually.


  • Open Access

    Bisphosphonates associated osteonecrosis of the jaw: A long‐term follow‐up of a series of 35 cases observed by GISL and evaluation of its frequency over time

    by Samantha Pozzi, Raffaella Marcheselli, Simona Falorio, Luciano Masini, Caterina Stelitano, Antonietta Falcone, Giovanni Quarta, Luisa Ponchio, Vincenzo Pitini, Stefano Luminari, et al.